AUSTIN, Texas

德克萨斯州奥斯汀

,

，

May 6, 2026

2026年5月6日

/PRNewswire/ -- Modicus Prime, a former resident at Johnson & Johnson Innovation – JLABS @ Texas Medical Center, announced today the completion of an additional $4.5M in funding led by Frist Cressey Ventures, bringing total funding to $8M with additional backing from Silverton Partners and Oncology Ventures.  The funding comes following the multiple rollouts of the .

/PRNewswire/ -- Modicus Prime，曾是强生创新-JLABS @德州医学中心的驻场公司，今天宣布完成了由Frist Cressey Ventures领投的额外450万美元融资，总融资额达到800万美元，同时还获得了来自Silverton Partners和Oncology Ventures的支持。此次融资是在多次产品推出之后获得的。

Trustworthy AI Compliance Software

可信的人工智能合规软件

enabling scalable, audit-ready AI systems across global pharmaceutical companies, CROs, CMOs, CDMOs, and adjacent regulated sectors.

使全球制药公司、合同研究组织（CRO）、合同制造组织（CMO）、合同开发和制造组织（CDMO）及相邻受监管领域的可扩展、审计就绪的AI系统成为可能。

Continue Reading

继续阅读

Figure 1. Depiction of Modicus Prime’s Trustworthy AI Compliance Software integrations and features enabling audit readiness of AI systems at scale

图1. Modicus Prime的可信AI合规软件集成和功能示意图，支持大规模AI系统的审计准备。

The Trustworthy AI Compliance Software enables pharmaceutical companies' AI applications in regulated (GxP) environments, both internal and from AI suppliers, to be audit-ready across their organizations.  It integrates with pharmaceutical tech stacks and quality management systems, acting as a central layer that enables scalable AI use across sites and geographies with varying regulatory requirements.

可信人工智能合规软件使制药公司的人工智能应用在受监管（GxP）环境中，无论是内部还是来自人工智能供应商的，都能在整个组织内做好审计准备。它与制药技术栈和质量管理系统相集成，充当一个中心层，能够在不同监管要求的站点和地域实现可扩展的人工智能使用。

The integration enables a single source of truth for compliance with global regulators including the FDA and EMA across the full AI lifecycle (see Figure 1). Translating between data science, IT, quality, and compliance, the software reduces operational friction and ensures every pharmaceutical stakeholder works compliantly with AI in regulated environments.

该集成确保了在整个人工智能生命周期中，遵循包括FDA和EMA在内的全球监管机构的单一真实数据源（见图1）。通过在数据科学、IT、质量和合规之间进行转换，该软件减少了运营摩擦，并确保每位制药利益相关者在受监管的环境中合规地使用人工智能。

The result is safer AI adoption, reduced compliance risk and protected ROI of AI investments, allowing pharma organizations to stay focused on delivering medicines to patients.  Compliant AI ultimately accelerates adoption at scale and helps reduce, for example, costly quality control failures costing the industry an estimated $50 billion annually..

结果是更安全的AI应用、更低的合规风险以及对AI投资回报的保护，使制药组织能够专注于为患者提供药物。合规的AI最终加速了大规模应用，并有助于减少例如每年给行业造成约500亿美元损失的昂贵质量控制失败等问题。

FCV founding partner Senator Bill Frist, MD states, 'At the end of the day, every advancement in this industry must serve the patient. By simplifying and strengthening AI compliance, Modicus Prime enables pharmaceutical leaders to stay focused on accelerating innovation and delivering life-saving therapies to those who need them most.'.

FCV创始合伙人、参议员比尔·弗里斯特医学博士表示：“最终，这个行业中的每一项进步都必须服务于患者。通过简化和加强AI合规性，Modicus Prime使制药业领导者能够专注于加速创新，并将挽救生命的疗法带给最需要它们的人。”

Modicus Prime's leadership is helping drive the industry's AI movement through authoring guidelines, keynotes, webinars, and talks informing regulators. Taylor Chartier, Modicus Prime's CEO, co-authored the

莫迪库斯·普莱姆的领导力正在通过制定指导方针、发表主题演讲、举办网络研讨会和讲座来帮助推动行业的AI运动，为监管者提供信息。莫迪库斯·普莱姆的首席执行官泰勒·查蒂尔与他人共同撰写了

ISPE GAMP AI Guide

ISPE GAMP AI指南

and BioPhorum AI Implementation publication in 2025.  She also spearheaded ISPE's GxP AI Webinar Series with fellow industry experts, which was an industry-first webinar series on implementing AI/ML solutions in GxP environments. Chartier continues to contribute to educational initiatives to upskill the pharmaceutical workforce in partnership with quality-focused organizations, including .

并在2025年发表了BioPhorum AI实施出版物。她还与业内其他专家共同领导了ISPE的GxP AI网络研讨会系列，这是业界首个关于在GxP环境中实施AI/ML解决方案的网络研讨会系列。查蒂埃继续通过与质量导向的组织合作，为提升制药行业劳动力技能的教育计划作出贡献，包括 。

Pathway for Patient Health

患者健康路径

.

。

A former engineer and data scientist from Shire and Bayer Pharmaceuticals, Chartier states, 'Pharmaceutical companies are investing heavily in AI, but without the infrastructure to deploy it compliantly and measure ROI, that investment is at risk. Adjacent healthcare sectors, including payers and providers, express the same need for compliance infrastructure.  This is the gap our Trustworthy AI Compliance Software addresses, enabling scalable AI adoption across regulated environments.'.

曾任职于Shire和拜耳制药的前工程师兼数据科学家查蒂尔表示：“制药公司正在大力投资人工智能，但如果没有能够合规部署并衡量投资回报率的基础设施，这些投资将面临风险。包括支付方和医疗服务提供者在内的相邻医疗保健领域也表达了对合规基础设施的相同需求。这正是我们的可信人工智能合规软件所解决的缺口，它能够推动在受监管环境中实现可扩展的人工智能应用。”

Oncology Ventures' Ben Freeberg states, 'The next wave of cancer breakthroughs are coming, and every manufacturer has to survive a regulatory audit to ensure those drugs get to patients who need them. Modicus Prime is the compliance layer that makes this happen.'

肿瘤学风险投资公司的本·弗里伯格表示：“下一波癌症治疗突破即将到来，每家制造商都必须通过监管审计，以确保这些药物能够送达需要它们的患者手中。Modicus Prime 就是实现这一目标的合规层。”

Modicus Prime is using this new capital to further service their international pharmaceutical customers with additional customer support, including the continued enhancement of its platform to better support customer deployments and growing AI compliance needs.

Modicus Prime 将利用这笔新资金进一步服务其国际制药客户，提供更多的客户支持，包括持续改进平台以更好地支持客户部署及不断增长的 AI 合规需求。

About Modicus Prime

关于Modicus Prime

Modicus Prime's AI Compliance platform bridges data science, IT, and quality, enabling regulated organizations to deploy and scale trustworthy AI.  By providing a single source of truth for regulators, the platform ensures AI applications remain compliant across their full lifecycle, from development through evolving GxP use.  A resident at Johnson & Johnson Innovation – JLABS @ South San Francisco, Modicus Prime is venture-backed and partners with leading pharmaceutical organizations to enable AI audit readiness at scale.  The platform integrates with existing tech stacks and quality management systems, supporting biologics, cell and gene therapies, and vaccine manufacturing across global regulatory environments..

Modicus Prime的AI合规平台连接数据科学、IT和质量领域，帮助受监管的组织部署和扩展可信赖的人工智能。通过为监管者提供统一的真实数据来源，该平台确保人工智能应用在其整个生命周期中保持合规，从开发到不断演变的GxP用途。作为强生创新旗下JLABS @南旧金山的驻场企业，Modicus Prime获得风险投资支持，并与领先的制药组织合作，实现大规模的AI审计准备。该平台与现有的技术堆栈和质量管理系统集成，支持在全球监管环境下的生物制品、细胞和基因疗法以及疫苗生产。

About Frist Cressey Partners

关于弗里斯特·克雷西合伙人

Founded by former U.S. Senate Majority Leader Bill Frist, MD and Bryan Cressey, Frist Cressey Ventures (FCV) is a healthcare venture capital firm with $846M AUM focused on accelerating the growth of high potential healthcare companies through a differentiated healthcare network, hands-on leadership support, and healthcare policy expertise.

由前美国参议院多数党领袖比尔·弗里斯特（Bill Frist）医生和布莱恩·克雷斯sey（Bryan Cressey）创立，弗里斯特克雷斯sey风险投资公司（Frist Cressey Ventures，简称FCV）是一家医疗保健风险投资公司，管理资产达8.46亿美元，专注于通过差异化的医疗网络、亲力亲为的领导支持以及医疗政策专业知识，加速高潜力医疗保健公司的成长。

Our mission is simple: to transform healthcare to improve lives. Our strategic partners, including The Cigna Group, MedStar Health and OhioHealth, provide healthcare to more than 50% of the U.S. population. We invest in early-stage startups that build technology or tech-enabled services to advance quality of care, system integration, patient outcomes, affordability, and access.

我们的使命很简单：通过转型医疗保健来改善生活。我们的战略合作伙伴，包括信诺集团、美德斯塔健康和俄亥俄健康，为超过50%的美国人口提供医疗服务。我们投资于早期初创企业，这些企业通过构建技术或技术支持的服务，提升护理质量、系统整合、患者疗效、可负担性和医疗可及性。

To learn more about Frist Cressey Ventures, visit our website at .

要了解有关Frist Cressey Ventures的更多信息，请访问我们的网站。

www.fcventures.com

www.fcventures.com

.

。

About Oncology Ventures

关于肿瘤学投资

Oncology Ventures is a specialized, Austin-based venture capital firm founded in 2022 by cancer survivor Ben Freeberg. The Fund invests in commercially-validated start-ups transforming the future of cancer care. Oncology Ventures is partnered with leading oncology institutions, including Texas Oncology, Fred Hutch Cancer Center, City of Hope, Moffitt and others..

肿瘤学风险投资公司是一家专业化的、位于奥斯汀的风险投资公司，由癌症幸存者本·弗里伯格于2022年创立。该基金投资于经过商业验证的初创企业，这些企业正在变革癌症治疗的未来。肿瘤学风险投资公司与领先的肿瘤学机构合作，包括德克萨斯肿瘤学、弗雷德·哈奇癌症中心、希望之城、莫菲特等。

Contact:

联系人：

Taylor Chartier

泰勒·查蒂尔

[email protected]

电子邮件地址

SOURCE Modicus Prime

源模数素

21

21

%

%

more press release views with

更多新闻发布视图与

Request a Demo

请求演示